Tabea Borde

Tabea Borde

Auto-generated profile, based on publicly available information

Tabea Borde

Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in Radiology
Verified
Journal Article
Closed access
TBTabea Borde
Tabea Borde
Nariman NezamiNariman Nezami
Nariman Nezami
FGFabian Max Laage Gaupp
Fabian Max Laage Gaupp
LSLynn Jeanette Savic
Lynn Jeanette Savic
TTTamar Taddei
Tamar Taddei
JCJulius Chapiro
Julius Chapiro
Restratification of patients with advanced-stage hepatocellular carcinomas according to enhancement-based, three-dimensional, quantitative tumor burden measurements identified patients who would be... Background Patients with intermediate- and advanced-stage hepatocellular carcinoma (HCC) represent a highly heterogeneous patient collective with substantial differences in overall survival. Purpos...

26 March 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
ABAntonia M. Berz
Antonia M. Berz
JSJessica G. Santana
Jessica G. Santana
SISimon Iseke
Simon Iseke
MGMoritz Gross
Moritz Gross
VPVasily Pekurovsky
Vasily Pekurovsky
JCJulius Chapiro
Julius Chapiro

30 May 2024 in International Journal of Computer Assisted Radiology and Surgery
Verified
Journal Article
Open access
PDF file
TBTabea Borde
Tabea Borde
LSLaetitia Saccenti
Laetitia Saccenti
MLMing Li
Ming Li
NVNicole A. Varble
Nicole A. Varble
LHLindsey A. Hazen
Lindsey A. Hazen
BWBradford J Wood
Bradford J Wood
Purpose: Targeting accuracy determines outcomes for percutaneous needle interventions. Augmented reality (AR) in IR may improve procedural guidance and facilitate access to complex locations. This study aimed to evaluate percutaneous needle placement accuracy using a goggle-based AR system compared to an ultrasound (US)-based fusion navigation system. Methods: Six interventional radiologists performed 24 independent needle placements in an anthropomorphic phantom (CIRS 057A) in four needle guidance cohorts (n = 6 each): (1) US-based fusion, (2) goggle-based AR with stereoscopically projected anatomy (AR-overlay), (3) goggle AR without the projection (AR-plain), and (4) CT-guided freehand. US-based fusion included US/CT registration with electromagnetic (EM) needle, transducer, and patient tracking. For AR-overlay, US, EM-tracked needle, stereoscopic anatomical structures and targets were superimposed over the phantom. Needle placement accuracy (distance from needle tip to target center), placement time (from skin puncture to final position), and procedure time (time to completion) were measured. Results: Mean needle placement accuracy using US-based fusion, AR-overlay, AR-plain, and freehand was 4.5 ± 1.7 mm, 7.0 ± 4.7 mm, 4.7 ± 1.7 mm, and 9.2 ± 5.8 mm, respectively. AR-plain demonstrated comparable accuracy to US-based fusion (p = 0.7) and AR-overlay (p = 0.06). Excluding two outliers, AR-overlay accuracy became 5.9 ± 2.6 mm. US-based fusion had the highest mean placement time (44.3 ± 27.7 s) compared to all navigation cohorts (p < 0.001). Longest procedure times were recorded with AR-overlay (34 ± 10.2 min) compared to AR-plain (22.7 ± 8.6 min, p = 0.09), US-based fusion (19.5 ± 5.6 min, p = 0.02), and freehand (14.8 ± 1.6 min, p = 0.002). Conclusion: Goggle-based AR showed no difference in needle placement accuracy compared to the commercially available US-based fusion navigation platform. Differences in accuracy and procedure times were apparent with different display modes (with/without stereoscopic projections). The AR-based projection of the US and needle trajectory over the body may be a helpful tool to enhance visuospatial orientation. Thus, this study refines the potential role of AR for needle placements, which may serve as a catalyst for informed implementation of AR techniques in IR.

13 October 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
SKSarah Keller
Sarah Keller
TBTabea Borde
Tabea Borde
JBJulia Brangsch
Julia Brangsch
LALisa Adams
Lisa Adams
AKAvan Kader
Avan Kader
MMMarcus Makowski
Marcus Makowski
To characterize the tumor extracellular matrix (ECM) using native T1 mapping magnetic resonance imaging (MRI) in an experimental hepatic cancer model, a total of 27 female New Zealand white rabbits with hepatic VX2 tumors were examined by MRI at different time points following tumor implantation (day 14, 21, 28). A steady-state precession readout single-shot MOLLI sequence was acquired in a 3 T MRI scanner in prone position using a head-neck coil. The tumors were segmented into a central, marginal, and peritumoral region in anatomical images and color-coded T1 maps. In histopathological sections, stained with H&E and Picrosirius red, the regions corresponded to central tumor necrosis and accumulation of viable cells with fibrosis in the tumor periphery. Another region of interest (ROI) was placed in healthy liver tissue. T1 times were correlated with quantitative data of collagen area staining. A two-way repeated-measures ANOVA was used to compare cohorts and tumor regions. Hepatic tumors were successfully induced in all rabbits. T1 mapping demonstrated significant differences between the different tumor regions (F(1.43,34.26) = 106.93, p < 0.001) without interaction effects between time points and regions (F(2.86,34.26) = 0.74, p = 0.53). In vivo T1 times significantly correlated with ex vivo collagen stains (area %), (center: r = 0.78, p < 0.001; margin: r = 0.84, p < 0.001; peritumoral: r = 0.73, p < 0.001). Post hoc tests using Sidak’s correction revealed significant differences in T1 times between all three regions (p < 0.001). Native T1 mapping is feasible and allows the differentiation of tumor regions based on ECM composition in a longitudinal tumor study in an experimental small animal model, making it a potential quantitative biomarker of ECM remodeling and a promising technique for future treatment studies.

20 December 2022 in European Radiology
Verified
Journal Article
Open access
PDF file
TBTabea Borde
Tabea Borde
MWMingming Wu
Mingming Wu
SRStefan Ruschke
Stefan Ruschke
CBChristof Boehm
Christof Boehm
JSJonathan Stelter
Jonathan Stelter
EFEva Maria Fallenberg
Eva Maria Fallenberg
Objectives: There is a clinical need for a non-ionizing, quantitative assessment of breast density, as one of the strongest independent risk factors for breast cancer. This study aims to establish proton density fat fraction (PDFF) as a quantitative biomarker for fat tissue concentration in breast MRI and correlate mean breast PDFF to mammography. Methods: In this retrospective study, 193 women were routinely subjected to 3-T MRI using a six-echo chemical shift encoding-based water-fat sequence. Water-fat separation was based on a signal model accounting for a single T2* decay and a pre-calibrated 7-peak fat spectrum resulting in volumetric fat-only, water-only images, PDFF- and T2*-values. After semi-automated breast segmentation, PDFF and T2* values were determined for the entire breast and fibroglandular tissue. The mammographic and MRI-based breast density was classified by visual estimation using the American College of Radiology Breast Imaging Reporting and Data System categories (ACR A-D). Results: The PDFF negatively correlated with mammographic and MRI breast density measurements (Spearman rho: −0.74, p < .001) and revealed a significant distinction between all four ACR categories. Mean T2* of the fibroglandular tissue correlated with increasing ACR categories (Spearman rho: 0.34, p < .001). The PDFF of the fibroglandular tissue showed a correlation with age (Pearson rho: 0.56, p = .03). Conclusion: The proposed breast PDFF as an automated tissue fat concentration measurement is comparable with mammographic breast density estimations. Therefore, it is a promising approach to an accurate, user-independent, and non-ionizing breast density assessment that could be easily incorporated into clinical routine breast MRI exams. Key Points: • The proposed PDFF strongly negatively correlates with visually determined mammographic and MRI-based breast density estimations and therefore allows for an accurate, non-ionizing, and user-independent breast density measurement. • In combination with T2*, the PDFF can be used to track structural alterations in the composition of breast tissue for an individualized risk assessment for breast cancer.

17 July 2020 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
TBTabea Borde
Tabea Borde
FGFabian Laage Gaupp
Fabian Laage Gaupp
JGJean-Francois Geschwind
Jean-Francois Geschwind
LSLynn J. Savic
Lynn J. Savic
MMMilena Miszczuk
Milena Miszczuk
JCJulius Chapiro
Julius Chapiro